Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline

2025-04-10 09:54:18 ET

Summary

• Protalix BioTherapeutics is rated a Strong Buy due to stable income, profitability, and potential from pipeline programs PRX-115 and PRX-119.
• Elelyso and Elfabrio provide recurring revenue, with increasing royalties expected, and the company has achieved a debt-free status and profitability.
• PRX-115 shows promise for gout treatment, potentially outperforming KRYSTEXXA, while PRX-119 targets NETs but remains speculative.
• Near-term catalysts include PRX-115 Phase II trial initiation, partnership updates, and potential buyout interest from Pfizer, despite high clinical and financial risks.

Introduction

Protalix BioTherapeutics ( PLX ) is a biotechnology company with two marketed therapies: Elelyso, for Gaucher disease, and Elfabrio for Fabry Disease. As well, the company is actively developing a clinical pipeline that, in our view, may open up further significant revenue opportunities....

Read the full article on Seeking Alpha

For further details see: